Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Regen BioPharma (RGBP) over the last 11 years, with Q3 2025 value amounting to 207.28%.

  • Regen BioPharma's EBIT Margin fell 634300.0% to 207.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 143.11%, marking a year-over-year increase of 332600.0%. This contributed to the annual value of 143.11% for FY2025, which is 332600.0% up from last year.
  • According to the latest figures from Q3 2025, Regen BioPharma's EBIT Margin is 207.28%, which was down 634300.0% from 69.0% recorded in Q2 2025.
  • Regen BioPharma's 5-year EBIT Margin high stood at 47.3% for Q1 2021, and its period low was 785.35% during Q4 2022.
  • Its 5-year average for EBIT Margin is 176.38%, with a median of 144.17% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -6051700bps in 2022, then soared by 5774700bps in 2023.
  • Over the past 5 years, Regen BioPharma's EBIT Margin (Quarter) stood at 180.18% in 2021, then crashed by -336bps to 785.35% in 2022, then surged by 74bps to 207.88% in 2023, then soared by 50bps to 103.92% in 2024, then crashed by -99bps to 207.28% in 2025.
  • Its EBIT Margin stands at 207.28% for Q3 2025, versus 69.0% for Q2 2025 and 191.91% for Q1 2025.